Reviewing Repros Therapeutics (RPRX) & Novelion Therapeutics (NVLN)

Repros Therapeutics (NASDAQ: RPRX) and Novelion Therapeutics (NASDAQ:NVLN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Repros Therapeutics and Novelion Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repros Therapeutics -4,242.73% -894.22% -230.71%
Novelion Therapeutics -108.10% -57.36% -11.88%

Risk and Volatility

Repros Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Novelion Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Insider and Institutional Ownership

13.6% of Repros Therapeutics shares are held by institutional investors. Comparatively, 75.6% of Novelion Therapeutics shares are held by institutional investors. 2.5% of Repros Therapeutics shares are held by company insiders. Comparatively, 14.1% of Novelion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Repros Therapeutics and Novelion Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Repros Therapeutics $50,000.00 379.78 -$17.27 million ($0.50) -0.96
Novelion Therapeutics $13.57 million 4.81 -$52.87 million ($6.99) -0.50

Repros Therapeutics has higher earnings, but lower revenue than Novelion Therapeutics. Repros Therapeutics is trading at a lower price-to-earnings ratio than Novelion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Repros Therapeutics and Novelion Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repros Therapeutics 0 1 0 0 2.00
Novelion Therapeutics 0 2 0 0 2.00

Repros Therapeutics presently has a consensus target price of $0.39, suggesting a potential downside of 18.75%. Novelion Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 128.57%. Given Novelion Therapeutics’ higher probable upside, analysts plainly believe Novelion Therapeutics is more favorable than Repros Therapeutics.

Summary

Novelion Therapeutics beats Repros Therapeutics on 8 of the 11 factors compared between the two stocks.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Novelion Therapeutics Company Profile

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply